Review
Oncology
Biyuan Xing, Jianfeng Guo, Yuhan Sheng, Gang Wu, Yingchao Zhao
Summary: HPV-negative cervical cancers, predominantly adenocarcinomas, pose challenges in diagnosis and management due to unclear etiology and possible false negative results. It is important to pay greater attention to these cases as they are often diagnosed at advanced stages with poor prognoses.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Boram Choi, Yoojin Na, Min Yeop Whang, Jung Yoon Ho, Mi-Ryung Han, Seong-Woo Park, Heekyoung Song, Soo Young Hur, Youn Jin Choi
Summary: In this study, the association between MGMT methylation and persistent HPV infection was examined using cervical cytology samples and a public database. The results showed that MGMT methylation was associated with HPV infection and downregulated MGMT mRNA expression correlated with poor overall survival. MGMT methylation level could potentially serve as a prognostic indicator for the transition from atypical squamous cells/low-grade squamous intraepithelial lesion to cervical cancer.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Andraz Dovnik, Mario Poljak
Summary: CIN2 is an intermediate stage between CIN1 and CIN3. Traditional treatment involved conization or ablative methods, but recent years have seen a shift towards conservative management for younger patients due to the possibility of spontaneous regression and adverse effects on future pregnancies. Research has focused on the role of host and HPV gene methylation to identify patients at higher risk of progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
An-Jen Chiang, Chia-Jung Li, Kuan-Hao Tsui, Chung Chang, Yuan-chin Ivan Chang, Li-Wen Chen, Tsung-Hsien Chang, Jim Jinn-Chyuan Sheu
Summary: The study found that UBE2C is highly expressed in human cervical squamous cell carcinoma (CESC) tissues and is related to clinical characteristics. In vitro experiments demonstrated that overexpression and knockdown of UBE2C respectively enhanced and reduced proliferation of cervical cancer cells. In vivo experiments showed that UBE2C regulates the expression and activity of the mTOR/PI3K/AKT pathway.
Article
Multidisciplinary Sciences
Xiaoyue Yang, Ying Chen, Mei Li, Weipei Zhu
Summary: ERBB3 gene mutation and methylation modification have extensive regulatory mechanisms on the microenvironment of cervical squamous cell carcinoma and endocervical adenocarcinoma. ERBB3 is more likely to be a carcinogenic factor rather than a prognostic factor for cervical cancer, and its carcinogenic mechanism is related to immune system suppression and RNA methylation. Methylation of ERBB3 may serve as an immunotherapy target in cervical squamous cell carcinoma and endocervical adenocarcinoma.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Leabaneng Tawe, Surbhi Grover, Nicola Zetola, Erle S. Robertson, Simani Gaseitsiwe, Sikhulile Moyo, Ishmael Kasvosve, Giacomo M. Paganotti, Mohan Narasimhamurthy
Summary: The study revealed a high promoter methylation rate of multiple tumor suppressor genes in cervical cancer patients, which was associated with increased risk of cervical cancer. Methylation of the RARB gene showed the strongest association with cervical cancer, and both cervical cancer and promoter methylation of RARB and DAPK1 genes were associated with increasing age.
FRONTIERS IN ONCOLOGY
(2021)
Article
Obstetrics & Gynecology
C. Acuti Martellucci, S. Nomura, D. Yoneoka, P. Ueda, J. M. L. Brotherton, K. Canfell, M. Palmer, L. Manzoli, P. Giorgi Rossi, A. De Togni, C. Palmonari, A. Califano, E. Saito, M. Hashizume, K. Shibuya
Summary: This retrospective cohort study in Italy assessed the effectiveness of an HPV vaccination programme in reducing the risk of cervical abnormalities detected during subsequent screenings. Results showed that women who received at least one dose of the HPV vaccine were significantly less likely to have abnormal cervical cytology. Overall, catch-up HPV vaccination almost halved the risk of cytological abnormalities in organized cervical screening programmes.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2021)
Article
Oncology
Mariam El-Zein, David Cheishvili, Moshe Szyf, Eduardo L. Franco
Summary: In this study, new methylation markers were identified and validated for their role in cervical intraepithelial neoplasia (CIN) grades and cervical cancer. The methylation state of CA10, DPP10, FMN2 and HAS1 genes were evaluated in independent study populations using next-generation sequencing. The Marker Polygenic Score (MPS) calculated from these genes accurately predicted cervical cancer and showed potential for use in clinical settings. Further evaluation of these biomarkers in prospective studies is needed.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Editorial Material
Oncology
Eduardo Franco
Summary: The American Cancer Society (ACS) believes that the time has come for primary human papillomavirus (HPV) screening in the United States, but it requires educating the public and healthcare providers and overcoming logistical barriers. ACS is taking the lead by utilizing its resources to promote primary HPV screening in the US and sharing best practices from other countries through its Primary HPV Screening Initiative.
Article
Oncology
Jacqueline M. Mix, Mona Saraiya, Trevor D. Thompson, Troy D. Querec, April Greek, Thomas C. Tucker, Edward S. Peters, Charles F. Lynch, Brenda Y. Hernandez, Glenn Copeland, Marc T. Goodman, Elizabeth R. Unger
Summary: The study compared HPV prevalence among high-grade cervical precancers and invasive cervical cancers before and after HPV vaccine availability. No significant reduction in vaccine-type prevalence was observed between the two studies, likely due to low HPV vaccination coverage among women in the postvaccine study. Monitoring HPV-type prevalence through population-based strategies remains important for evaluating the impact of the HPV vaccine.
Review
Virology
Kimia Sharifian, Zabihollah Shoja, Somayeh Jalilvand
Summary: In recent decades, it has become well-established that human papillomavirus can cause tumors, and research is actively investigating the genetic and environmental factors that determine whether viral infection is eliminated or develops into cancer. The microbiota has emerged as an important factor that can influence this balance by either enhancing or reducing the ability of viral infection to promote cancer. In the female reproductive system, the vaginal microbiota plays a crucial role in maintaining health and preventing pathogenic infections. A diverse vaginal microbiota with reduced abundance of Lactobacillus spp. has been found to contribute to HPV acquisition, persistence, and the development of cervical cancer. This review explores the role of normal female reproductive tract microbiota in health, the mechanisms by which dysbiosis can lead to disease through interactions with microbes, and various therapeutic approaches.
Review
Virology
Zahra Salavatiha, Mohammad Farahmand, Zabihollah Shoja, Somayeh Jalilvand
Summary: This study found varying HPV prevalence among women in Iran with different cervical cytology statuses, and suggests integrating HPV vaccines into the national vaccination programs of Iran for beneficial outcomes.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Oncology
Luhan Zhang, Hong Yu, Tian Deng, Li Ling, Juan Wen, Mingfen Lv, Rongying Ou, Qiaozhi Wang, Yunsheng Xu
Summary: The study revealed that key genes involved in HPV-mediated cervical carcinogenesis include those related to DNA replication/repair and cell cycle, with significant metabolic shifts observed. FNDC3B and BPGM were identified as key genes in the transformation from normal epithelium to precancerous lesions and cervical cancer. Higher FNDC3B expression or lower BPGM expression were associated with shorter overall survival and disease-free survival in patients with cervical cancer.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Chetna Yadav, Ritu Yadav, Ravindresh Chabbra, Smiti Nanda, Shalu Ranga, Lokesh Kadian, Parul Ahuja
Summary: Cervical cancer is a common cancer in women worldwide, particularly in low- and middle-income countries. HPV plays a crucial role in its development by interfering with the host's signaling pathways. Aberrant genetic mutations, polymorphisms, and epigenetic mechanisms affect the apoptotic pathways involved in cervical carcinogenesis. Non-coding RNAs have also been implicated in epigenetic regulation of various malignancies, including cervical cancer. This review focuses on genetic and epigenetic approaches to target apoptosis and HPV genes, as well as novel drug molecules currently in clinical trials for cervical cancer treatment.
Article
Oncology
Ran Zhou, Zhuo Chen, Zuo-Run Xiao, Shou-Li Wang, Chao Rong
Summary: Persistent high-risk HPV infection plays a significant role in tumor development in various human malignancies, with a focus on cervical cancer. This study revealed a strong prognostic potential of HPV-related gene promoter methylation signature in classifying CC patients into high-risk and low-risk groups with distinct clinical outcomes. Clinical trials in large cohorts of CC patients are crucial for the implementation of epigenetic biomarkers in better clinical management.
FRONTIERS IN ONCOLOGY
(2021)
Meeting Abstract
Economics
L. Iadeluca, E. Farrington, T. McLean, B. Rousseau, Y. Agosti, J. Absalon, A. S. Anderson
Article
Health Care Sciences & Services
Jean-Ju Sheen, Laura Reimers, Shravya Govindappagari, Ivan M. Ngai, Diana Garretto, Roopali Donepudi, Pamela Tropper, Dena Golfman, Ashlesha K. Dayal, Peter S. Bernstein
Summary: This study aimed to improve patient handoffs on the labor floor by introducing the mnemonic SWIFT and formalized curricula for resident training, resulting in gradual improvements in completeness, clarity, and overall quality of handoff information.
JOURNAL OF PATIENT SAFETY
(2021)
Article
Oncology
Laura Iadeluca, Jack Mardekian, Pratibha Chander, Markay Hopps, Geoffrey T. Makinson
CANCER MANAGEMENT AND RESEARCH
(2017)
Article
Oncology
Andrew Trigg, Masami Kelly, Laura Iadeluca, Jane Chang, Alejandro Moreno-Koehler, Andrew Yaworsky, Meaghan Krohe, Alex Rider, Joseph C. Cappelleri, David Cella, Kim Cocks
Summary: The study evaluated the psychometric performance of NFOSI-18 in advanced ovarian cancer, demonstrating acceptable reliability and construct validity of NFOSI-18 scores, along with provided guidance on clinically important differences.
Article
Economics
Fredrik O. L. Nilsson, Sandra T. Asanin, Elizabeth T. Masters, Laura Iadeluca, Chrissy Almond, Miranda Cooper, Sarah Smith
Summary: The study suggests that second- or third-line+ lorlatinib is cost-effective for ALK-positive NSCLC patients compared to chemotherapy in Sweden, with ICERs below the country's cost-effectiveness threshold for high-severity diseases.
Article
Oncology
David Waterhouse, Laura Iadeluca, Sneha Sura, Keith Wilner, Birol Emir, Stan Krulewicz, Janet Espirito, Lauren Bartolome
Summary: The study found that crizotinib showed clinical benefit in patients with ROS1-positive advanced NSCLC in a US community oncology setting, but the patients were older with a higher proportion of smokers.
Article
Oncology
Gabriel Tremblay, Michael Groff, Laura Iadeluca, Patrick Daniele, Keith Wilner, Robin Wiltshire, Lauren Bartolome, Tiziana Usari, Joseph C. Cappelleri, D. Ross Camidge
Summary: This study compares the clinical trial results of crizotinib and entrectinib in ROS1-positive non-small-cell lung cancer and compares the clinical trial data of crizotinib with real-world outcomes. The study finds that crizotinib and entrectinib have comparable efficacy in treating ROS1-positive non-small-cell lung cancer.
Article
Economics
Sarah Smith, Fernando Albuquerque de Almeida, Monica Ines, Laura Iadeluca, Miranda Cooper
Summary: This study compared the efficacy of lorlatinib and chemotherapy for patients with advanced ALK-positive non-small cell lung cancer. Lorlatinib showed a significant improvement in progression-free survival compared to chemotherapy. Limited evidence suggested that lorlatinib also improved overall survival compared to systemic therapy.
Article
Oncology
Julien Mazieres, Laura Iadeluca, Alice T. Shaw, Benjamin J. Solomon, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Dong-Wan Kim, Tony Mok, Arlene Reisman, Holger Thurm, Anna M. Polli, Geoffrey Liu
Summary: This study presents detailed patient-reported outcome data from a phase 3 study comparing lorlatinib with crizotinib in previously untreated ALK-positive advanced NSCLC patients. The results show that both drugs improved quality of life, functioning, and symptom scores during treatment. Lorlatinib showed better improvements in several symptoms, while crizotinib performed better in cognitive functioning.
Article
Critical Care Medicine
Benjamin J. Solomon, Todd M. Bauer, Tony S. K. Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylan Lopez Lopez, Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip
Summary: After 3 years of follow-up, lorlatinib showed durable benefit over crizotinib in treatment-naive ALK-positive non-small-cell lung cancer patients, indicating the potential use of lorlatinib as a first-line treatment option.
LANCET RESPIRATORY MEDICINE
(2023)
Article
Oncology
Toshiaki Takahashi, Makoto Nishio, Kazumi Nishino, Yasumasa Yoshiki, Naoko Shiraiwa, Birol Emir, Laura Iadeluca, Yasushi Yatabe, Kazuto Nishio
Summary: Our study found that sequential biomarker testing may result in longer time to treatment compared to simultaneous single biomarker testing. The Oncomine Dx target test (ODxTT), a next-generation sequencing-based multiplex biomarker panel test, has been approved in Japan and is expected to improve time to treatment. This retrospective observational study analyzed reimbursement data for lung cancer patients in Japan and showed that the use of ODxTT increased over time and contributed to a shorter time to treatment compared to single biomarker tests.
Article
Economics
Jaesh Naik, Norma Beavers, Fredrik O. L. Nilsson, Laura Iadeluca, Chrissy Lowry
Summary: This study investigated the cost-effectiveness of lorlatinib as a first-line treatment for ALK-positive NSCLC in Sweden. The results showed that lorlatinib was a cost-effective option compared to crizotinib, alectinib, and brigatinib.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY
(2023)
Article
Oncology
Laura L. Reimers, Mandy Goldberg, Parisa Tehranifar, Karin B. Michels, Barbara A. Cohn, Julie D. Flom, Ying Wei, Piera Cirillo, Mary Beth Terry
Summary: This study found that women with self-reported BBD had higher mammographic breast density than women without BBD, particularly in women diagnosed with BBD before their first birth.
BREAST CANCER RESEARCH
(2021)
Article
Immunology
Marla J. Keller, Robert D. Burk, L. Stewart Massad, Isam-Eldin Eltoum, Nancy A. Hessol, Kathryn Anastos, Xianhong Xie, Howard Minkoff, Xiaonan Xue, Laura L. Reimers, Mark Kuniholm, Gypsyamber D'Souza, Christine Colie, Bradley Aouizerat, Joel M. Palefsky, Howard D. Strickler
Article
Health Care Sciences & Services
Markay Hopps, Laura Iadeluca, Margaret McDonald, Geoffrey T. Makinson
JOURNAL OF MULTIDISCIPLINARY HEALTHCARE
(2017)
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)